Curasight A /S announced that it is expanding and accelerating its clinical programs with two additional cancer indications - Neuroendocrine tumors (NET) and head and neck cancer. Both indications will be pursued with regard to both diagnostics and therapy meaning that Curasight strengthens its position as a theranostic company. With reference to the recently published positive results from the investigator-initiated phase II studies performed by researchers at Rigshospitalet, using the uTRACE technology in both Neuroendocrine tumors (NET) and head and neck cancer, Curasight has decided also to further develop uTRACE for use in these two indications in order to obtain FDA approval in 2026.

This will be added to the current program with uTRACE in brain cancer, which is still the lead indication both within diagnostics and therapy, in addition to prostate cancer. The expectation is still to get uTRACE approved for use in brain cancer in 2025. Going forward, Curasight's clinical development in diagnostics (uTRACE) will thus include two additional phase III studies, comprising neuroendocrine tumors (NET) besides head - neck cancer, which strengthens the strategic position with uTRACE as a diagnostic platform and increases the commercial opportunities considerably.

Similarly, Curasight will also develop a therapeutic option (uTREAT) for neuroendocrine tumors (NET) and head and neck cancer in addition to brain cancer. For a smaller group of samples, a broad suite of elements was analysed by analytical method is a Na2O2 fusion.